974.25
-2.03%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Windlas Biotech
Its shares trade on NSE under the ticker WINDLAS.NS. It has been listed since 16 August 2021. In the fiscal year to 31 March 2026, it reported revenue of ₹9.04bn and net income of ₹664.6m. At that date it held total assets of ₹9.07bn and shareholders' equity of ₹5.81bn.
Windlas Biotech Ltd. operates as a contract development and manufacturing organization (CDMO). The company employs 1,049 full-time employees The company went IPO on 2021-08-16. The firm provides a range of contract development and manufacturing organization (CDMO) services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. Its therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry and respiratory therapies. The Company’s service capabilities include formulation development, technology scale-up and full-scale commercial manufacturing. The company has capabilities for both solid and liquid pharmaceutical dosage forms. The firm markets its own manufactured nutraceutical, pharmaceutical and ayurvedic products to serve the semi-urban and rural communities. The company also has a salesforce and distribution network spread across over 14 states. The Company’s manufacturing facilities are located at Dehradun in Uttarakhand.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 16 Aug 2021
- Employees
- 1,049
- Website
- windlas.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Windlas Biotech Ltd employs 1,049 full-time employees for CDMO services.
- Windlas Biotech operates manufacturing facilities in Dehradun, Uttarakhand for pharmaceutical production.
- Windlas Biotech markets nutraceutical and ayurvedic products to semi-urban and rural communities.
Weaknesses
- Windlas Biotech's IPO was on 16 August 2021, a relatively recent listing.
- Windlas Biotech's service capabilities are limited to solid and liquid pharmaceutical dosage forms.
- Windlas Biotech's salesforce covers only 14 states across India.
Opportunities
- Windlas Biotech can expand its therapeutic categories to include anti-diabetic and cardiovascular therapies.
- Windlas Biotech can leverage its formulation development capabilities for new product discovery.
- Windlas Biotech can grow its distribution network beyond 14 Indian states.
Threats
- Windlas Biotech faces competition from other CDMOs in the Indian Health Care sector.
- Windlas Biotech's reliance on Dehradun for manufacturing may pose supply chain risks.
- Windlas Biotech's focus on semi-urban and rural markets may limit its growth potential.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.